#OnoPharmaceutical

Announcement of scheduled reappointment of all six directors as of April 1, 2026, and at the shareholders meeting planned for June 2026, along with changes in executive officers.

As of March 31, 2026, the distribution and sales of Forxiga® Tablets in Japan will be transferred from Ono Pharmaceutical Co., Ltd. to AstraZeneca, and joint promotion will end. The sales forecast for fiscal 2026 is 80 billion yen.

For FY2026 Q3, revenue was 397.0 billion yen (6.0% YoY increase), operating income was 88.2 billion yen (24.8% YoY increase), and quarterly profit was 68.9 billion yen (21.8% YoY increase).